(Q36768244)

16 August 2017

1 reference

title

New studies influencing treatment of heart failure: 2006 update (English)

1 reference

16 August 2017

Mark E Dunlap

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

4 Pt 2

1 reference

16 August 2017

page(s)

3S-11S

1 reference

Long-Term Trends in the Incidence of and Survival with Heart Failure

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Angiotensin receptor blockers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Sleep apnea and heart failure: Part II: central sleep apnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Continuous positive airway pressure for central sleep apnea and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4PART2.3S

10.1592/PHCO.27.4PART2.3S

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference